CIMA Labs Inc.
Division of Teva Pharmaceutical Industries Ltd.
Latest From CIMA Labs Inc.
Review of oral, nasal and intravenous abuse-deterrence claims for Teva's long-acting hydrocodone Vantrela ER highlights the lack of head-to-head studies against approved abuse-deterrent formulations and spurs debate on relevant comparators.
Human abuse liking study, in vitro data paint different pictures of potential for hydrocodone extended-release product to deter oral abuse, FDA says ahead of advisory committee review; agency finds support for abuse-deterrent claims for intranasal, intravenous use.
The Dealmaking column is a survey of recent transactions, including strategic alliances, mergers & acquisitions, and financings, in the life sciences industries. Deals are listed by the following industry sectors: in vitro diagnostics, medical devices, pharmaceuticals, and research/analytical instrumentation and reagents. All transactions are excerpted from Elsevier's Strategic Transactions database, providing comprehensive transaction coverage from 1991 to the present.
- Drug Delivery
- Therapeutic Areas
- North America
- Parent & Subsidiaries
- Teva Pharmaceutical Industries Ltd.
- Senior Management
James C Hawley, CFO
Douglas E Moran, Dir., Bus. Dev.
- Contact Info
CIMA Labs Inc.
Phone: (952) 947-8700
10000 Valley View Rd.
Eden Prairie, MN 55344
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.